Biotech releases Phase 1 respiratory therapy results following premature poster exposure

Generate:Biomedicines presented initial clinical data for its respiratory disease candidate at the European Respiratory Society meeting, after its posters were accidentally made public two weeks early. The company had intended to delay the disclosure until the conference. The Phase 1 findings mark an early step in evaluating the drug's safety and activity.